The TRANSCEND study, as I mentioned, there were two dose levels that were studied for liso-cel. One is monotherapy, the other in combination with ibrutinib. The monotherapy or single agent cohort has been previously reported at other meetings. The combination cohort has not yet been reported. And the single agent cohort showed that again, there’s activity, particularly in a heavily pretreated population of patients...
The TRANSCEND study, as I mentioned, there were two dose levels that were studied for liso-cel. One is monotherapy, the other in combination with ibrutinib. The monotherapy or single agent cohort has been previously reported at other meetings. The combination cohort has not yet been reported. And the single agent cohort showed that again, there’s activity, particularly in a heavily pretreated population of patients. Liso-cel is safe in patients with CLL, with a reasonable expectation for cytokine release and neurotoxicity that’s very manageable. And I think the important point with the monotherapy cohort that’s being presented is the durability around those responses that we’ve seen with single agent liso-cel in a heavily pretreated population of patients.